Dizhe Pharmaceuticals (688192.SH): Suwozhe receives expedited approval for listing on the US FDA market

Zhtng Cijng APP news, Dzh yyo (688192.SH) announcement, the company's independently developed drug Shw zh (English trade name: ZEGFROVY, generic name: shw tn pin) new drug application (NDA) has officially been approved by the US Food and Drug Administration (FDA), for use in adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) 20 exon insertion mutation (Exon20ins) who have disease progression after or during platinum-based chemotherapy and confirmed by FDA-approved test kits.